Patrick Ozark

Patrick Ozark

  • Bioinformatics Analyst I

Departments

Divisions

Education 

BA – Washington and Lee University, Computer Science

Honors & Awards

  • 2017  Finalist; American Society for Nutrition Emerging Leaders in Nutrition Science Poster Competition
  • 2017  Abstract selected for a talk; Experimental Biology Annual Meeting
  • 2015  Abstract selected for a talk; American Physiological Society Conference: Cardiovascular, Renal, and Metabolic Diseases: Physiology and Gender
  • 2015  American Physiological Society Abstract Oral Travel Award

Research Interests

I am interested in the development and application of computational tools that leverage next-generation sequencing data to reveal latent medical knowledge and advance our understanding of disease. My overarching goal is to understand the molecular basis of cancer through elucidating the regulatory relationship between genotype and phenotype on a genome-wide scale, and how disruption in regulation contributes to the pathogenesis, maintenance, and progression of disease. These insights can be exploited to inform the creation of targeted therapies for more effective and personalized patient care.

Selected Publications

Cao K, Ugarenko M, Ozark PA, Wang J, Marshall SA, Rendleman EJ, Liang K, Wang L, Zou L, Smith ER, Yue F, Shilatifard A (in press): DOT1L controlled cell fate determination and transcription elongation are independent of H3K79 methylation. PNAS.

Sze CC, Ozark PA, Cao K, Ugarenko M, Das S, Wang L, Marshall SA, Rendleman EJ, Ryan CA, Zha D, Douillet D, Chen FX, Shilatifard A: Coordinated regulation of cellular identity-associated H3K4me3 breadth by the COMPASS family. Sci Adv 2020, 6(26): eaaz4764. doi.org/10.1126/sciadv.aaz4764

Qi J, Esfahani DR, Huang T, Ozark P, Bartom E, Hashizume R, Bonner ER, An S, Horbinski CM, James CD, Saratsis AM: Tenascin-C expression contributes to pediatric brainstem glioma tumor phenotype and represents a novel biomarker of disease. Acta Neuropathol Commun 2019, 7(75). doi.org/10.1186/s40478-019-0727-1

Wang L, Ozark PA, Smith ER, Zhao Z, Marshall SA, Rendleman EJ, Piunti A, Ryan C, Whelan AL, Helmin KA, Morgan MA, Zou L, Singer BD, Shilatifard A: TET2 coactivates gene expression through demethylation of enhancers. Sci Adv 2018, 4(11):eaau6986. doi.org/10.1126/sciadv.aau6986

Saleiro D, Blyth GT, Kosciuczuk EM, Ozark PA, Majchrzak-Kita B, Arslan AD, Fischietti M, Reddy NK, Horvath CM, Davis RJ, Fish EN, Platanias LC: IFN-g-inducible antiviral responses require ULK1 mediated activation of MLK3 and ERK5. Sci Signal 2018, 11(557). doi.org/10.1126/scisignal.aap9921

Liang K, Smith ER, Aoi Y, Stoltz KL, Katagi H, Woodfin AR, Rendleman EJ, Marshall SA, Murray DC, Wang L, Ozark PA, Mishra RK, Hashizume R, Schiltz GE, Shilatifard A: Targeting Processive Transcription Elongation via SEC Disruption for MYC-Induced Cancer Therapy. Cell 2018, 175(3):766-779.e17. doi.org/10.1016/j.cell.2018.09.027

Wang L, Zhao Z, Ozark PA, Fantini D, Marshall SA, Rendleman EJ, Cozzolino KA, Louis N, He X, Morgan MA, Takahashi YH, Collings CK, Smith ER, Ntziachristos P, Savas JN, Zou L, Hashizume R, Meeks JJ, Shilatifard A: Resetting the epigenetic balance of Polycomb and COMPASS function at enhancers for cancer therapy. Nat Med 2018, 24(6):758-769. doi.org/10.1038/s41591-018-0034-6

Chen FX, Xie P, Collings CK, Cao K, Aoi Y, Marshall SA, Rendleman EJ, Ugarenko M, Ozark PA, Zhang A, Shiekhattar R, Smith ER, Zhang MW, Shilatifard A: PAF1 regulation of promoter-proximal pause release via enhancer activation. Science 2017, 357(6357):1294-1298. doi.org/10.1126/science.aan3269

Full list of publications

Last update: October 2020

For updates on COVID-19, please read.